Rentschler Biopharma SE hires new Vice President Biopharma Engineering & Technology Dr. Thomas Rösch

Rentschler Biopharma SE hires new Vice President Biopharma Engineering & Technology Dr. Thomas Rösch

Rentschler Biopharma_150x38

Press Release | Rentschler Biotechnologie GmbH

MAY 08, 2018

Laupheim, Germany – Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today that Dr. Thomas Rösch (49) will join the Company as Vice President Biopharma Engineering & Technology, effective April 1, 2018. He will be responsible for advanced biopharmaceutical engineering projects to enhance site and capacity, in line with the Company’s strategy. Dr. Rösch has more than 16 years of industry experience, including senior leadership positions in engineering, maintenance and project management within pharma, biopharma and research & development.

“Dr. Thomas Rösch has excellent biopharmaceutical process and construction expertise and will drive our major technology and capacity expansion projects,” said Dr. Ralf Otto, COO of Rentschler Biopharma SE. “With his exceptional knowledge and experience of pharma and biopharma infrastructure projects we are, now, perfectly positioned to maximize our efforts in the further development and optimization of our manufacturing facilities. Dr. Rösch’s understanding of improving existing and building up new sites globally will accelerate our expansion in line with our clients’ needs.”

Dr. Thomas Rösch added: “The CDMO sector is entering a very exciting phase driven by new technologies and modalities. Together with the Rentschler Biopharma team, we will further evolve our footprint by optimizing process engineering and technology applications. It will be thrilling to contribute to the successful implementation of Rentschler Biopharma’s strategy.”

Prior to joining Rentschler Biopharma, Dr. Rösch held the position of Head of Global Engineering & Technology Pharma & Chemicals at Boehringer Ingelheim Pharma GmbH & Co KG., Ingelheim, Germany. In his previous role as Project Lead Organizational Redesign Launch & Production Site Germany, he was responsible for the transformation of Boehringer Ingelheim’s largest production site. Dr. Rösch gained international experience during a three year assignment as Director Infrastructure at Boehringer Ingelheim’s production site in Columbus, Ohio, USA. At Boehringer, he started as a project manager for large CapEx projects up to € 70 million and subsequently led the Biopharmaceutical and R, D & M Engineering teams. Dr. Rösch started his industrial career in an engineering firm after finishing his PhD at the University of Kassel, Germany. He also became Associate Professor for mechanical and thermal engineering at the University of Biberach, Germany, in 2009.

About Rentschler Biopharma SE

Rentschler Biopharma SE, located in Laupheim, Germany, is a leading contract development and manufacturing organization (CDMO) for bioprocess development and manufacturing of biopharmaceuticals as well as for related consulting activities in terms of project management and regulatory support. The Company’s clients include innovative biotech companies and major pharmaceutical companies around the world. Many years of experience and excellence in finding solutions as well as certified quality management and advanced technologies ensure Rentschler Biopharma’s high quality standards. Rentschler Biopharma is a family-owned company employing approximately 800 people. For further information, please visit:

Media Contacts

Dr. Alexander Starnecker, Rentschler Biopharma SE MC
Tel: +49-7392701-211

Raimund Gabriel, Managing Partner, MC Services AG
Tel: +49-89-210228-36


Click on Rentschler Biopharma SE hires new Vice President Biopharma Engineering & Technology Dr. Thomas Rösch for other information.
Click on Rentschler Biotechnologie to contact the company directly.

Supplier Information
Supplier: Rentschler Biotechnologie GmbH
Address: Erwin-Rentschler-Str. 21, 88471 Laupheim, Germany
Tel: +49 7392 701-0
Fax: +49 7392 701-300

Comments are closed.